Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. (Q54373489)
Jump to navigation
Jump to search
scientific article published on 3 March 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. |
scientific article published on 3 March 2014 |
Statements
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer. (English)
Valentina Guarneri
Daniele Giulio Generali
Antonio Frassoldati
Fabrizio Artioli
Corrado Boni
Luigi Cavanna
Alberto Bottini
Katia Cagossi
Giancarlo Bisagni
Guido Ficarra
Enrica Roncaglia
Simona Nuzzo
Ramona Swaby
Catherine Ellis
Clare Holford
Pierfranco Conte
3 March 2014
32
10
1050-1057